Detection of prostate-specific antigen (PSA) as a screening strategy for prostate cancer is limited by the inability of the PSA test to differentiate between malignant cancer and benign hyperplasia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback